The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > LATEST
LATEST
-
BUSINESS Abecma Approved for Earlier Lines of MM Therapy in Japan: BMS
December 7, 2023
-
REGULATORY CEFP Discusses Social Security Reform Timeline, No Surprises for Pharma Measures
December 6, 2023
-
BUSINESS Pfizer to Cut Ties with 3 Regional Wholesalers, Further Narrowing Expected
December 5, 2023
-
REGULATORY Authorized Generics Cannot be Regulated Now but Must Be Watched Closely: MHLW Panel Members
December 5, 2023
-
BUSINESS Shionogi Hooks Up with Life Science VC AN Venture Partners
December 5, 2023
-
BUSINESS Preliminary Injunction for Sprycel Generic “Extremely Unjust”: Sawai
December 5, 2023
-
REGULATORY 500 Billion Yen-Plus Annual Savings Expected from Generic Switches: Reiwa Rincho
December 5, 2023
-
REGULATORY Japan Eyes Stronger OTC Sales Restrictions Due to Drug Abuse
December 4, 2023
-
REGULATORY Reliance on Drug Price Cuts to Pool Financial Resources Must End: LDP Lawmakers
December 4, 2023
-
REGULATORY Narrower Drug Price Gap Likely Due to Inflation, Efforts on Fair-Priced Distributions: Minister
December 4, 2023
-
BUSINESS Ono Doubles Investment in Corporate Venture Fund to US$200 Million
December 4, 2023
-
REGULATORY Proposed Introduction of Elective Care Scheme for LLP Copay “Hard to Understand”: Chuikyo Members
December 4, 2023
-
REGULATORY Transitional Pneumovax Program for Age 70 and Up Set to End in March
December 4, 2023
-
REGULATORY PMDA Reviewing Safety Risks for Carvykti, Keytruda, Tecentriq, and More
December 4, 2023
-
BUSINESS Padcev/Keytruda Combo Gets FDA Priority Review for Bladder Cancer
December 4, 2023
-
REGULATORY Pharma Groups Lobby Firmly against Expansion of CEA Price Adjustments: LDP Hearing
December 4, 2023
-
BUSINESS Torii, BioCryst Revise Deal for HAE Drug Orladeyo in Japan
December 1, 2023
-
REGULATORY FY2023 Extra Budget Clears Diet, 1.4 Billion Yen to Boost Drug Production
December 1, 2023
-
REGULATORY Council OKs Public-Knowledge Application for Truvada Use as PrEP for HIV
December 1, 2023
-
BUSINESS Eisai Unit Joins Hands with Thai Authorities on Dementia Drug Access
December 1, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…